| Clinical Trials.gov Identifier | Location and Investigator | Title of the study | Purpose | Start Date | Completion date | Cells involved |
| NCT01943383 | Julie A Johnson, Pharm D. University of Florida, USA | Pharmacogenomic evaluation of antihypertensive responses in iPSC study (PEAR-iPSC) | To study the variation in responsiveness of antihypertensive drug therapy in different individuals. | August 2013 | October 2016 | iPSCs |
| NCT02246491 | Sonia Franco, MD. Sidney Kimmel Comprehensive Cancer Center, John Hopkins, USA | iPSC-based approaches for modelling and treating Ataxia-Telangiectasia | To understand the disease mechanism of Ataxia-Telangiectasia (A-T) using patient fibroblast derived iPSC in vitro. | October 2014 | October 2017 | iPSCs |
| NCT02193724 | Rachel C. Brennan, MD St. Jude Children’s Research Hospital (University of Wisconsin, Madison, USA: collaborator) | Feasibility, validation and differentiation of iPSC produced from patients with heritable retinoblastoma | To establish the feasibility of producing iPSCs from retinoblastoma patients with germline RB1 mutations, validate the derivative cells and differentiate them into retina as a model of the initiation of retinoblastoma in the developing retina. | October 2014 | April 2017 | iPSCs |
| NCT02056613 | David F Stroncek, M.DNational Institutes of Health Clinical Centre, USA | Blood collection from healthy volunteers and patients for the production of clinical grade iPSC products. | To develop new methods to make iPSCs; to identify better ways to collect, produce, and grow them; and to make an iPSC bank. | January 2014 | October 2018 | iPSCs |
| NCT00874783 | Benjamin E Reubinoff, MD., PhD. Hadassah Medical Organization, USA | Derivation of iPSCs from somatic cells donated by patients with neurological diseases for the study of the pathogenesis of the disorders and development of novel therapies. | The major goal of the project is to develop human iPSCs from cell cultures from skin biopsies or the patient’s hair for modelling diseases and drug discovery and for developing the technology that may eventually allow the use of iPS cells for future transplantation therapy. | April, 2009 | December, 2018 | iPSCs |